A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT00566449 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Placebo
DRUG: JNJ-31001074
DRUG: JNJ-31001074

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.